Navigation Links
Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
Date:11/5/2013

BALTIMORE, Nov. 5, 2013 /PRNewswire/-- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO).  Her responsibilities include managing the Company's business, clinical, financial, licensing, and corporate development efforts.  Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008.

Under her leadership, Alba Therapeutics established a collaborative funding agreement on February 9, 2011 with Cephalon Pharmaceuticals (now Teva Pharmaceuticals) and has taken a leading role in advancing multiple clinical studies in Celiac Disease.  The company has conducted seven clinical trials in subjects with Celiac Disease and is currently conducting a large Phase IIb trial with the lead compound Larazotide Acetate. 

"Ms. Perrow brings a wealth of global experience and leadership with a proven track record of success in both biotech and pharmaceutical companies," said Bruce Peacock Co-Chairman of Alba. "Wendy is a key member of our leadership team, driving deal making as well as clinical and financial strategy and her experience in leading successful research and development and commercial infrastructures has been invaluable to Alba."

Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global and U.S. marketing for Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... Calif., Feb. 10, 2011 PRO-DEX, INC. (Nasdaq: ... quarter and six months ended December 31, 2010. ... 8% to $6.2 million from $5.7 million for the corresponding ... the Company,s medical device products to its largest customer, and ...
... Cephalon, Inc. (Nasdaq: CEPH ) today reported ... compared to net sales of $2.152 billion for 2009.  Basic ... amortization expense and certain other items, adjusted net income for ... over the previous year.  This exceeded the company,s adjusted net ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 2Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 4Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 5Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 6Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 7Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 2Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 3Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 4Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 5Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 6Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 7Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 8Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 9Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 10Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 11Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 12Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 13Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 14Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 15
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ( http://evermaya.com/ ), ... handbag line will be named for Madeline Stuart, an 18-year-old model from Brisbane, ... recognized model with Down syndrome, gracing the front pages of publications across the ...
(Date:7/31/2015)... Minn. (PRWEB) , ... July 31, 2015 , ... ... is selected as a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) ... designed to help long-term and post-acute care providers understand the benefits of using ...
(Date:7/31/2015)... York (PRWEB) , ... July 31, 2015 , ... Physical therapy for ... limits the patient's quality of life. It keeps the patient from doing what they want ... and may have a hard time using the stairs. The patient's exercise regime may be ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Radiology Business ... Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol Hill” ... founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of the ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent ... Court in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini ... docket entry was made recording the minutes of the status conference, which was held ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... , , ... agenda of events, education sessions, new product introductions and a wide ... launched its annual Allscripts Client Experience (ACE) ... 2,700 attendees registered for the conference, driven by strong interest in ...
... /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ... of the Company, will present at the Canaccord Adams 29th ... August 11, 2009 at 3:30 p.m. ET. , Interested parties ... the "Events" section of the homepage of the Company,s website ...
... ... ... $4,240 $5,215 ... 22%, Diluted EPS from Continuing Operations $0.51 $0.41, Special ...
... ... of Family Crisis. , ... (PRWEB) -- Once upon a time Denise found herself in the midst of a crisis. ... accident involving his son. She was very close to her brother and he needed her ...
... ... in PA, after the creative director lost his beloved mother to ARDS. Accent Media donated ... , ... 27, 2009 -- Acute Respiratory Distress Syndrome (ARDS) may not be one of the most ...
... autoimmune disease systemic lupus erythematosus (SLE) have an increased ... immune responses and treatment with immunosuppressive drugs. Because morbidity ... patients, it is recommended that patients with SLE get ... increase disease activity. Both antibody and cell-mediated responses are ...
Cached Medicine News:Health News:Allscripts User Conference Draws 2,700, Sets Attendance Record 2Health News:Allscripts User Conference Draws 2,700, Sets Attendance Record 3Health News:Allscripts User Conference Draws 2,700, Sets Attendance Record 4Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 2Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 3Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 4Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 5Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 6Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 7Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 8Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 9Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 10Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 11Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 12Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 13Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 14Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 15Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 16Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 17Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 18Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 19Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 20Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 21Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 22Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 23Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 24Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 25Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 26Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 27Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 28Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 29Health News:Prepaid Emergency Travel Announces a Unique Service That Provides Peace of Mind During Family Emergencies 2Health News:ARDS Promotes Awareness with New Campaign 2Health News:Immune responses to flu vaccine are diminished in lupus patients 2
... 130 has expanded memory capabilities for overnight sleep ... retain oxygen saturation and pulse rate data, and ... suit your needs:, ,1. The Model 130 ... for a single patient, making the device ideally ...
... continuous, or spot check pulse ... and an internal rechargeable battery. ... Study modes make it ideal ... or clinical environment; during emergency ...
... The Autocorr Plus, the fourth ... cost-effective, versatile pulse oximeter/ECG/Respiration Monitor, with ... detect/reject, digital oximetry with SAC (Serial ... high-resolution electroluminescent screen display provides two ...
... Management Program is a Windows based, easy-to-use ... Hand-Held Pulse Oximeter. Using the Smiths ... it rapidly downloads information collected during sleep ... and assists in the Clinician's interpretation by ...
Medicine Products: